Pub Date : 2025-04-24DOI: 10.1016/j.imr.2025.101149
Ming Yang , Yue Chen , Yuxiang Wan , Chen Shen , Jinchang Huang
Acupuncture and moxibustion are increasingly gaining recognition in the clinical and research fields of integrative oncology. This review synthesizes findings from clinical guidelines, systematic reviews, meta-analyses, and randomized controlled trials (RCTs) of acupuncture and moxibustion for cancer care. Clinical evidence highlights acupuncture’s efficacy in managing symptoms such as hot flashes, pain, insomnia, fatigue, and constipation. Acupuncture also demonstrates potential effects in reducing chemotherapy and radiotherapy-induced side effects. Recent advancements in China shows integrated therapies combining acupuncture with chemotherapy to enhance therapeutic outcomes. Additionally, laboratory studies reveal the potential of acupuncture and moxibustion to modulate the tumor microenvironment, boost chemotherapy efficacy, and strengthen immunity. Despite these promising results, there is a pressing need for well-designed trials and real-world studies to evaluate the long-term effects of standardized acupuncture and moxibustion treatments in cancer care.
{"title":"Acupuncture and moxibustion in integrative oncology and new progress in China","authors":"Ming Yang , Yue Chen , Yuxiang Wan , Chen Shen , Jinchang Huang","doi":"10.1016/j.imr.2025.101149","DOIUrl":"10.1016/j.imr.2025.101149","url":null,"abstract":"<div><div>Acupuncture and moxibustion are increasingly gaining recognition in the clinical and research fields of integrative oncology. This review synthesizes findings from clinical guidelines, systematic reviews, meta-analyses, and randomized controlled trials (RCTs) of acupuncture and moxibustion for cancer care. Clinical evidence highlights acupuncture’s efficacy in managing symptoms such as hot flashes, pain, insomnia, fatigue, and constipation. Acupuncture also demonstrates potential effects in reducing chemotherapy and radiotherapy-induced side effects. Recent advancements in China shows integrated therapies combining acupuncture with chemotherapy to enhance therapeutic outcomes. Additionally, laboratory studies reveal the potential of acupuncture and moxibustion to modulate the tumor microenvironment, boost chemotherapy efficacy, and strengthen immunity. Despite these promising results, there is a pressing need for well-designed trials and real-world studies to evaluate the long-term effects of standardized acupuncture and moxibustion treatments in cancer care.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101149"},"PeriodicalIF":2.8,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-23DOI: 10.1016/j.imr.2025.101148
Wen-Li Yan , Zun-Qi Kan , Li-Qiong Wang , Zhen-Ping Yu , Cun-Zhi Liu , Shi-Yan Yan , Na-Na Yang
Background
The purpose of this study was to conduct a network meta-analysis (NMA) comparing the effectiveness and safety of traditional acupuncture with metformin. This study aims to identify an effective and safe alternative treatment for women with polycystic ovary syndrome (PCOS) complicated by insulin resistance (IR).
Methods
We searched PubMed, EMBASE, Web of Science, Cochrane, ClinicalTrials.gov, and relevant citations for eligible randomized controlled trials (RCTs) published up to August 12, 2024. Data extraction and bias assessment were performed by two independent reviewers, and Bayesian NMA was performed using the GeMTC package, with a random effects model. The NMA compared the effectiveness and safety of acupuncture with metformin which were measured using the Homeostasis Model Assessment Insulin Resistance (HOMA-IR) index, fasting plasma glucose, fasting insulin, and the incidence of adverse events (AEs).
Results
We included 12 RCTs (n = 870). Four RCTs compared acupuncture with metformin, six compared metformin with control interventions (blank control or placebo), and two compared acupuncture with sham acupuncture. Acupuncture (Mean difference (MD): -0.76, 95 % credible interval (CrI): -1.42, -0.03) and metformin (MD: -0.74, 95 % CrI: -1.28, -0.17) significantly reduced the IR level (HOMA-IR). No statistical difference was observed between both treatment methods in improving glucose metabolism; however, acupuncture had fewer AEs (risk ratio: 0.13, 95 % CrI: 0.01, 0.68). Acupuncture all ranked high in terms of surface under the cumulative ranking curve across all outcomes, thus demonstrating better effectiveness and safety potential.
Conclusions
Acupuncture may be a potential alternative for PCOS women with IR, as it is equally effective, easier to perform, and relatively safer than metformin. Further trials are necessary to confirm these findings owing to the current lack of sufficient evidence.
{"title":"Comparative effectiveness and safety of acupuncture vs metformin in insulin-resistant polycystic ovary syndrome women: A network meta-analysis of RCTs","authors":"Wen-Li Yan , Zun-Qi Kan , Li-Qiong Wang , Zhen-Ping Yu , Cun-Zhi Liu , Shi-Yan Yan , Na-Na Yang","doi":"10.1016/j.imr.2025.101148","DOIUrl":"10.1016/j.imr.2025.101148","url":null,"abstract":"<div><h3>Background</h3><div>The purpose of this study was to conduct a network meta-analysis (NMA) comparing the effectiveness and safety of traditional acupuncture with metformin. This study aims to identify an effective and safe alternative treatment for women with polycystic ovary syndrome (PCOS) complicated by insulin resistance (IR).</div></div><div><h3>Methods</h3><div>We searched PubMed, EMBASE, Web of Science, Cochrane, ClinicalTrials.gov, and relevant citations for eligible randomized controlled trials (RCTs) published up to August 12, 2024. Data extraction and bias assessment were performed by two independent reviewers, and Bayesian NMA was performed using the GeMTC package, with a random effects model. The NMA compared the effectiveness and safety of acupuncture with metformin which were measured using the Homeostasis Model Assessment Insulin Resistance (HOMA-IR) index, fasting plasma glucose, fasting insulin, and the incidence of adverse events (AEs).</div></div><div><h3>Results</h3><div>We included 12 RCTs (<em>n</em> = 870). Four RCTs compared acupuncture with metformin, six compared metformin with control interventions (blank control or placebo), and two compared acupuncture with sham acupuncture. Acupuncture (Mean difference (MD): -0.76, 95 % credible interval (CrI): -1.42, -0.03) and metformin (MD: -0.74, 95 % CrI: -1.28, -0.17) significantly reduced the IR level (HOMA-IR). No statistical difference was observed between both treatment methods in improving glucose metabolism; however, acupuncture had fewer AEs (risk ratio: 0.13, 95 % CrI: 0.01, 0.68). Acupuncture all ranked high in terms of surface under the cumulative ranking curve across all outcomes, thus demonstrating better effectiveness and safety potential.</div></div><div><h3>Conclusions</h3><div>Acupuncture may be a potential alternative for PCOS women with IR, as it is equally effective, easier to perform, and relatively safer than metformin. Further trials are necessary to confirm these findings owing to the current lack of sufficient evidence.</div><div><em>Protocol registration</em>: PROSPERO, CRD42024581934.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101148"},"PeriodicalIF":2.8,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144067946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-23DOI: 10.1016/j.imr.2025.101147
Matthew J Leach , Simon DuBois , Reine DuBois
Background
Although consumer demand and practitioner interest in integrative health care (IHC) have amplified over the past few decades, the patient experience of IHC still remains poorly understood. This study aimed to explore patient’s experiences of receiving care within an IHC setting in Australia.
Methods
Adults that had accessed an IHC setting within the past 12 months were invited to participate in a national, cross-sectional study. Individuals meeting the inclusion criteria were asked to complete the 57-item Integrative Healthcare Experience Tool (iHEET), online.
Results
A total of 327 participants completed the iHEET (82.3 % female; 92.9 % aged 30 years or older). Participants reported a generally favourable experience of IHC, as indicated by an overall IHC experience score of 4.19 ± 0.90 (mean ± SD). Mean experience subscores were high for 8 of the 12 IHC experience domains (i.e. respectful, personalised, patient-centred, holistic, interdisciplinary, evidence-based, communicative, wellness-focussed), and moderate for 4 of the 12 domains (i.e. non-hierarchical, collaborative, coordinated, accessible).
Conclusion
The findings of this novel study suggest IHC practice in Australia closely aligns with the philosophy and framework of IHC, and is mostly congruent with what patients want from an IHC service. Notwithstanding, there are several areas where IHC services could improve in order to optimise the patient experience. These areas include providing care that is more visibly collaborative and coordinated, and enabling equitable access to services for diverse patient populations.
{"title":"Patient Experiences of Integrative health CarE [PEICE]: A cross-sectional study","authors":"Matthew J Leach , Simon DuBois , Reine DuBois","doi":"10.1016/j.imr.2025.101147","DOIUrl":"10.1016/j.imr.2025.101147","url":null,"abstract":"<div><h3>Background</h3><div>Although consumer demand and practitioner interest in integrative health care (IHC) have amplified over the past few decades, the patient experience of IHC still remains poorly understood. This study aimed to explore patient’s experiences of receiving care within an IHC setting in Australia.</div></div><div><h3>Methods</h3><div>Adults that had accessed an IHC setting within the past 12 months were invited to participate in a national, cross-sectional study. Individuals meeting the inclusion criteria were asked to complete the 57-item Integrative Healthcare Experience Tool (iHEET), online.</div></div><div><h3>Results</h3><div>A total of 327 participants completed the iHEET (82.3 % female; 92.9 % aged 30 years or older). Participants reported a generally favourable experience of IHC, as indicated by an overall IHC experience score of 4.19 ± 0.90 (mean ± SD). Mean experience subscores were high for 8 of the 12 IHC experience domains (i.e. respectful, personalised, patient-centred, holistic, interdisciplinary, evidence-based, communicative, wellness-focussed), and moderate for 4 of the 12 domains (i.e. non-hierarchical, collaborative, coordinated, accessible).</div></div><div><h3>Conclusion</h3><div>The findings of this novel study suggest IHC practice in Australia closely aligns with the philosophy and framework of IHC, and is mostly congruent with what patients want from an IHC service. Notwithstanding, there are several areas where IHC services could improve in order to optimise the patient experience. These areas include providing care that is more visibly collaborative and coordinated, and enabling equitable access to services for diverse patient populations.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101147"},"PeriodicalIF":2.8,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-22DOI: 10.1016/j.imr.2025.101146
Ye-Chae Hwang , Jungkuk Lee , Dongwoo Kang , Han-Gyul Lee , Seungwon Kwon , Seung-Yeon Cho , Seong-Uk Park , Woo-Sang Jung , Sang-Kwan Moon , Jung-Mi Park , Jungtae Leem , Chang-Nam Ko
Background
Idiopathic Parkinson’s disease (IPD) has been associated with increased global mortality. While acupuncture has been reported to slow IPD progression, its effect on mortality remains unclear. This study investigated the association between acupuncture exposure and mortality, causes of death, and prognosis in patients with IPD.
Methods
Using customized cohort data from the National Health Insurance Service (NHIS), we analyzed patients newly diagnosed with IPD without disabilities between 2012 and 2016. Patients were classified into an acupuncture group (≥six sessions within 1 year of diagnosis) and a non-acupuncture group. Propensity score matching (PSM) was applied, and Cox proportional hazards models were used for survival analysis. During a 6-year follow-up, hazard ratios (HRs) were estimated for overall and cause-specific mortality, emergency room visits, fractures, and the first deep brain stimulation (DBS) procedure, using the non-acupuncture group as the reference.
Results
After PSM, 6394 patients were included in each group. The HR for mortality in the acupuncture group was 0.887 (95 % CI: 0.813−0.967), indicating a significantly lower mortality risk. Deaths due to neoplasms and digestive diseases were also lower in the acupuncture group. No significant differences were observed between groups in fracture risk, emergency room visits, or DBS procedures.
Conclusions
Acupuncture exposure was associated with a reduced mortality rate in patients with IPD. These findings suggest potential benefits of integrating acupuncture into IPD management, though further long-term randomized controlled trials are needed to confirm these results.
{"title":"A nationwide retrospective cohort study of the association between acupuncture exposure and clinical outcomes of idiopathic Parkinson’s disease using health insurance claim data in South Korea","authors":"Ye-Chae Hwang , Jungkuk Lee , Dongwoo Kang , Han-Gyul Lee , Seungwon Kwon , Seung-Yeon Cho , Seong-Uk Park , Woo-Sang Jung , Sang-Kwan Moon , Jung-Mi Park , Jungtae Leem , Chang-Nam Ko","doi":"10.1016/j.imr.2025.101146","DOIUrl":"10.1016/j.imr.2025.101146","url":null,"abstract":"<div><h3>Background</h3><div>Idiopathic Parkinson’s disease (IPD) has been associated with increased global mortality. While acupuncture has been reported to slow IPD progression, its effect on mortality remains unclear. This study investigated the association between acupuncture exposure and mortality, causes of death, and prognosis in patients with IPD.</div></div><div><h3>Methods</h3><div>Using customized cohort data from the National Health Insurance Service (NHIS), we analyzed patients newly diagnosed with IPD without disabilities between 2012 and 2016. Patients were classified into an acupuncture group (≥six sessions within 1 year of diagnosis) and a non-acupuncture group. Propensity score matching (PSM) was applied, and Cox proportional hazards models were used for survival analysis. During a 6-year follow-up, hazard ratios (HRs) were estimated for overall and cause-specific mortality, emergency room visits, fractures, and the first deep brain stimulation (DBS) procedure, using the non-acupuncture group as the reference.</div></div><div><h3>Results</h3><div>After PSM, 6394 patients were included in each group. The HR for mortality in the acupuncture group was 0.887 (95 % CI: 0.813−0.967), indicating a significantly lower mortality risk. Deaths due to neoplasms and digestive diseases were also lower in the acupuncture group. No significant differences were observed between groups in fracture risk, emergency room visits, or DBS procedures.</div></div><div><h3>Conclusions</h3><div>Acupuncture exposure was associated with a reduced mortality rate in patients with IPD. These findings suggest potential benefits of integrating acupuncture into IPD management, though further long-term randomized controlled trials are needed to confirm these results.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101146"},"PeriodicalIF":2.8,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-15DOI: 10.1016/j.imr.2025.101145
Zun-Yuan Li , Chun-Lan Chen , Xiao-Yan Li , Wen-Ge Huo , Yan Yang , Yu-Hong Guo , Zhi-Dan Liu
Background
Moxibustion has been applied in various clinical treatments, including chemotherapy-induced leukopenia. Using a Bayesian network meta-analysis, this study assessed a wide range of published data to identify the most efficient and effective method of moxibustion therapy for treating chemotherapy-induced leukopenia.
Methods
PubMed, EMBASE, and eight other databases plus two clinical trial registration platforms were searched from their respective inception date to January 2024. All randomized controlled trials (RCTs) of moxibustion for chemotherapy-induced leukopenia were included. The primary outcome indicator was white blood cell count, and the secondary outcome was the Karnofsky performance status score. Stata (version 17.0) and the gemtc package (version 1.0–0) of R (version 4.3.1) were used to perform the network meta-analysis. This study is registered in the International Prospective Register of Systematic Reviews (PROSPERO) database, registration number CRD42023402588.
Results
Thirty RCTs with 2282 total patients involving 12 types of moxibustion-related therapies were identified. Results of the surface under the cumulative ranking curve revealed the following treatments as most effective for leukopenia: thunder-fire moxibustion combined with medication (95.9 %), grain-sized moxibustion combined with medication (76.2 %), and herb-separated moxibustion (76.0 %). Grain-sized moxibustion combined with medication (76.5 %) ranked first in improving Karnofsky performance status scores.
Conclusion
Thunder-fire moxibustion combined with medication appears to be the most effective treatment for chemotherapy-induced leukopenia.
{"title":"Comparative efficacy of moxibustion in chemotherapy-induced leukopenia: A Bayesian network meta-analysis","authors":"Zun-Yuan Li , Chun-Lan Chen , Xiao-Yan Li , Wen-Ge Huo , Yan Yang , Yu-Hong Guo , Zhi-Dan Liu","doi":"10.1016/j.imr.2025.101145","DOIUrl":"10.1016/j.imr.2025.101145","url":null,"abstract":"<div><h3>Background</h3><div>Moxibustion has been applied in various clinical treatments, including chemotherapy-induced leukopenia. Using a Bayesian network meta-analysis, this study assessed a wide range of published data to identify the most efficient and effective method of moxibustion therapy for treating chemotherapy-induced leukopenia.</div></div><div><h3>Methods</h3><div>PubMed, EMBASE, and eight other databases plus two clinical trial registration platforms were searched from their respective inception date to January 2024. All randomized controlled trials (RCTs) of moxibustion for chemotherapy-induced leukopenia were included. The primary outcome indicator was white blood cell count, and the secondary outcome was the Karnofsky performance status score. Stata (version 17.0) and the gemtc package (version 1.0–0) of R (version 4.3.1) were used to perform the network meta-analysis. This study is registered in the International Prospective Register of Systematic Reviews (PROSPERO) database, registration number CRD42023402588.</div></div><div><h3>Results</h3><div>Thirty RCTs with 2282 total patients involving 12 types of moxibustion-related therapies were identified. Results of the surface under the cumulative ranking curve revealed the following treatments as most effective for leukopenia: thunder-fire moxibustion combined with medication (95.9 %), grain-sized moxibustion combined with medication (76.2 %), and herb-separated moxibustion (76.0 %). Grain-sized moxibustion combined with medication (76.5 %) ranked first in improving Karnofsky performance status scores.</div></div><div><h3>Conclusion</h3><div>Thunder-fire moxibustion combined with medication appears to be the most effective treatment for chemotherapy-induced leukopenia.</div></div><div><h3>Protocol registration</h3><div>PROSPERO, CRD42023402588.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101145"},"PeriodicalIF":2.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143878663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-11DOI: 10.1016/j.imr.2025.101144
Yiqing Cai , Guoyan Yang , Yibo Liu , Xiangyun Zou , Heng Yin , Xinyan Jin , Xuehan Liu , Chenlu Wang , Nicola Robinson , Jianping Liu
Background
Singing bowl has traditionally been utilized to promote healing and relaxation. This systematic review aimed to analyze all available clinical evidence, and determine any beneficial or adverse effects of singing bowl in any population.
Methods
Databases searched included PubMed, Embase, the Cochrane Library, PsyINFO, CINAHL, CNKI, VIP, Wanfang, Sinomed from database inception to July 2024. Clinical studies of singing bowl therapy, regardless of research type, population, and intervention were included. The risk of bias of randomized controlled trials (RCTs) was assessed using the Cochrane tool. Data from randomized trials were analyzed and presented as the mean difference with 95 % confidence interval, and the results from two or more separate trials with same study type that evaluated similar populations, interventions, comparisons and outcomes were statistical pooled using meta-analysis by Stata.16 software.
Results
Nineteen clinical studies originated from eight countries and published between 2008 and 2024 were identified. Half were RCTs (9), the remainder included case series studies (7), randomized crossover studies (2) and non-RCT (1). Evidence showed that singing bowl has been applied to a wide range of conditions, including the elderly, surgery, Parkinson's disease, pain, cancer, neurological function, sleep disorder, depression, anxiety, autism spectrum disorder, as well as physiological and psychological function, and it has mainly focused on outcomes related to mental health.
Conclusion
Singing bowl may have potential to alleviate anxiety, depression, improve quality of sleep and cognitive function in various patient groups, and change autistic behavior. It also shows potential benefits in physiological improvements like electroencephalography.
{"title":"Therapeutic effects of singing bowls: A systematic review of clinical studies","authors":"Yiqing Cai , Guoyan Yang , Yibo Liu , Xiangyun Zou , Heng Yin , Xinyan Jin , Xuehan Liu , Chenlu Wang , Nicola Robinson , Jianping Liu","doi":"10.1016/j.imr.2025.101144","DOIUrl":"10.1016/j.imr.2025.101144","url":null,"abstract":"<div><h3>Background</h3><div>Singing bowl has traditionally been utilized to promote healing and relaxation. This systematic review aimed to analyze all available clinical evidence, and determine any beneficial or adverse effects of singing bowl in any population.</div></div><div><h3>Methods</h3><div>Databases searched included PubMed, Embase, the Cochrane Library, PsyINFO, CINAHL, CNKI, VIP, Wanfang, Sinomed from database inception to July 2024. Clinical studies of singing bowl therapy, regardless of research type, population, and intervention were included. The risk of bias of randomized controlled trials (RCTs) was assessed using the Cochrane tool. Data from randomized trials were analyzed and presented as the mean difference with 95 % confidence interval, and the results from two or more separate trials with same study type that evaluated similar populations, interventions, comparisons and outcomes were statistical pooled using meta-analysis by Stata.16 software.</div></div><div><h3>Results</h3><div>Nineteen clinical studies originated from eight countries and published between 2008 and 2024 were identified. Half were RCTs (9), the remainder included case series studies (7), randomized crossover studies (2) and non-RCT (1). Evidence showed that singing bowl has been applied to a wide range of conditions, including the elderly, surgery, Parkinson's disease, pain, cancer, neurological function, sleep disorder, depression, anxiety, autism spectrum disorder, as well as physiological and psychological function, and it has mainly focused on outcomes related to mental health.</div></div><div><h3>Conclusion</h3><div>Singing bowl may have potential to alleviate anxiety, depression, improve quality of sleep and cognitive function in various patient groups, and change autistic behavior. It also shows potential benefits in physiological improvements like electroencephalography.</div></div><div><h3>Protocol registration</h3><div>PROSPERO, CRD42025639808.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101144"},"PeriodicalIF":2.8,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-31DOI: 10.1016/j.imr.2025.101143
Nguyen Thi Thu Ha , Duong Trong Nghia , Ha Thi Viet Nga , Trinh Thi Lua , Nguyen Thi Bich Hong , Nguyen Thi Hanh , Nguyen Kim Ngoc , Nguyen Lam Vuong
Background
Knee osteoarthritis (KOA) is a leading cause of disability among older adults worldwide. Traditional medicine offers a promising treatment for KOA with fewer side effects compared to current treatments such as non-steroidal anti-inflammatory drugs and corticosteroids. This study aimed to evaluate the safety and efficacy of TD0015, a herbal formulation based on the Duhuo Jisheng decoction, in treating KOA.
Methods
This randomized, double-blind, placebo-controlled trial enrolled 108 patients with KOA. Participants were randomly assigned in a 1:1:1 ratio to receive TD0015 5 g, TD0015 7.5 g, or placebo daily for 60 days. Efficacy endpoints included changes in Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), Visual Analogue Scale (VAS), Lequesne index, heel-buttock distance, and knee flexion and extension range of motion. Safety was assessed by adverse events (AEs).
Results
The mean age was around 60 years, and >80 % were females. Both TD0015 treatment groups significantly improved the WOMAC, VAS, Lequesne score, heel-buttock distance, and knee flexion and extension during the treatment period. At the 90-day follow-up, the mean percentage improvement in WOMAC scores was 74.5 % ± 13.4 %, 83.9 % ± 14.8 %, and 7.4 % ± 31.5 % in the TD0015 5 g, TD0015 7.5 g, and placebo groups, respectively, which corresponds to a 67.1 % (95 % CI: 56.3–77.9) and 76.5 % (95 % CI: 65.6–87.4) improvement in the TD0015 5 g and TD0015 7.5 g groups, compared to placebo. No AEs were reported in any group.
Conclusions
The Vietnamese herbal medicine TD0015 is safe, efficacious, and well-tolerated in treating KOA. Further studies are required to confirm the long-term efficacy and safety of TD0015.
{"title":"Traditional Vietnamese herbal medicine TD0015 in Knee Osteoarthritis: A Phase-II randomized controlled trial","authors":"Nguyen Thi Thu Ha , Duong Trong Nghia , Ha Thi Viet Nga , Trinh Thi Lua , Nguyen Thi Bich Hong , Nguyen Thi Hanh , Nguyen Kim Ngoc , Nguyen Lam Vuong","doi":"10.1016/j.imr.2025.101143","DOIUrl":"10.1016/j.imr.2025.101143","url":null,"abstract":"<div><h3>Background</h3><div>Knee osteoarthritis (KOA) is a leading cause of disability among older adults worldwide. Traditional medicine offers a promising treatment for KOA with fewer side effects compared to current treatments such as non-steroidal anti-inflammatory drugs and corticosteroids. This study aimed to evaluate the safety and efficacy of TD0015, a herbal formulation based on the Duhuo Jisheng decoction, in treating KOA.</div></div><div><h3>Methods</h3><div>This randomized, double-blind, placebo-controlled trial enrolled 108 patients with KOA. Participants were randomly assigned in a 1:1:1 ratio to receive TD0015 5 g, TD0015 7.5 g, or placebo daily for 60 days. Efficacy endpoints included changes in Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), Visual Analogue Scale (VAS), Lequesne index, heel-buttock distance, and knee flexion and extension range of motion. Safety was assessed by adverse events (AEs).</div></div><div><h3>Results</h3><div>The mean age was around 60 years, and >80 % were females. Both TD0015 treatment groups significantly improved the WOMAC, VAS, Lequesne score, heel-buttock distance, and knee flexion and extension during the treatment period. At the 90-day follow-up, the mean percentage improvement in WOMAC scores was 74.5 % ± 13.4 %, 83.9 % ± 14.8 %, and 7.4 % ± 31.5 % in the TD0015 5 g, TD0015 7.5 g, and placebo groups, respectively, which corresponds to a 67.1 % (95 % CI: 56.3–77.9) and 76.5 % (95 % CI: 65.6–87.4) improvement in the TD0015 5 g and TD0015 7.5 g groups, compared to placebo. No AEs were reported in any group.</div></div><div><h3>Conclusions</h3><div>The Vietnamese herbal medicine TD0015 is safe, efficacious, and well-tolerated in treating KOA. Further studies are required to confirm the long-term efficacy and safety of TD0015.</div></div><div><h3>Trial registration</h3><div>ClinicalTrials.gov, NCT06657495.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101143"},"PeriodicalIF":2.8,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-31DOI: 10.1016/j.imr.2025.101142
Jeremy Y. Ng
Brain-computer interfaces (BCIs) represent a transformative innovation in healthcare, enabling direct communication between the brain and external devices. This educational article explores the potential intersection of BCIs and traditional, complementary, and integrative medicine (TCIM). BCIs have shown promise in enhancing mind-body practices such as meditation, while their integration with energy-based therapies may offer novel insights and measurable outcomes. Emerging advancements, including artificial intelligence-enhanced BCIs, hold potential for improving personalization and expanding the therapeutic efficacy of TCIM interventions. Despite these opportunities, integrating BCIs with TCIM presents considerable ethical, cultural, and practical challenges. Concerns related to informed consent, cultural sensitivity, data privacy, accessibility, and regulatory frameworks must be addressed to ensure responsible implementation. Interdisciplinary collaboration among relevant stakeholders, including TCIM and conventional practitioners, researchers, and policymakers among other relevant stakeholders is crucial for developing integrative healthcare models that balance innovation with patient safety and respect for diverse healing traditions. Future directions include expanding evidence bases to validate TCIM practices through BCI-enhanced research, fostering equitable access to neurotechnological advancements, and promoting global ethical guidelines to navigate complex sociocultural dynamics. BCIs have the potential to revolutionize TCIM, offering novel solutions for complex health challenges and fostering a more inclusive, integrative approach to healthcare, provided that they are utilized responsibly and ethically.
{"title":"Exploring the intersection of brain-computer interfaces and traditional, complementary, and integrative medicine","authors":"Jeremy Y. Ng","doi":"10.1016/j.imr.2025.101142","DOIUrl":"10.1016/j.imr.2025.101142","url":null,"abstract":"<div><div>Brain-computer interfaces (BCIs) represent a transformative innovation in healthcare, enabling direct communication between the brain and external devices. This educational article explores the potential intersection of BCIs and traditional, complementary, and integrative medicine (TCIM). BCIs have shown promise in enhancing mind-body practices such as meditation, while their integration with energy-based therapies may offer novel insights and measurable outcomes. Emerging advancements, including artificial intelligence-enhanced BCIs, hold potential for improving personalization and expanding the therapeutic efficacy of TCIM interventions. Despite these opportunities, integrating BCIs with TCIM presents considerable ethical, cultural, and practical challenges. Concerns related to informed consent, cultural sensitivity, data privacy, accessibility, and regulatory frameworks must be addressed to ensure responsible implementation. Interdisciplinary collaboration among relevant stakeholders, including TCIM and conventional practitioners, researchers, and policymakers among other relevant stakeholders is crucial for developing integrative healthcare models that balance innovation with patient safety and respect for diverse healing traditions. Future directions include expanding evidence bases to validate TCIM practices through BCI-enhanced research, fostering equitable access to neurotechnological advancements, and promoting global ethical guidelines to navigate complex sociocultural dynamics. BCIs have the potential to revolutionize TCIM, offering novel solutions for complex health challenges and fostering a more inclusive, integrative approach to healthcare, provided that they are utilized responsibly and ethically.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101142"},"PeriodicalIF":2.8,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-25DOI: 10.1016/j.imr.2025.101141
Jeffery A. Dusek , Qi Gao , Ryung S. Kim , Donald I. Abrams , Benjamin Kligler , Natalie L. Dyer , Kathryn Hansen , Eric J. Roseen , M. Diane McKee , the PRIMIER Writing Group*
Background
An increasing number of clinics are providing integrative medicine for chronic pain, creating a need for real-world, practice-based research. Our purpose was to conduct a multi-site prospective, practice-based, observational evaluation of patient reported outcomes in chronic pain patients.
Methods
This study took place at seventeen BraveNet Practice Based Research Network integrative medicine clinics. Chronic pain patients receiving personalized, integrative medicine interventions at BraveNet clinics were eligible. Participants completed the Patient Reported Outcomes Measurement Information System-29, Perceived Stress Scale-4, and the Patient Activation Measure at the index/baseline visit and at 2, 4, 6, and 12 months. Diagnostic and billing codes were extracted data from patients’ health records. Linear mixed-model and multi-variate analyses evaluated changes from index visit through 12 months.
Results
A total of 4883 patients enrolled, 3658 qualified and 967 of them endorsed chronic pain, completed at least two outcomes at 2 time points, had evaluable electronic health record data, and had at least one integrative medicine visit during the study period. Participants had a mean age of 51.6 years (SD 13.88) and were mostly white (81.8 %), female (78.3 %), educated (≥ college degree: 70.1 %). Significant improvements were observed on all 7 Patient Reported Outcomes Measurement Information System subscales, Perceived Stress Scale, and Patient Activation Measure scores at 12 months.
Conclusions
Chronic pain patients receiving care at integrative medicine clinics reported significant improvement over time in multiple domains of pain and quality of life. Future research with more sites and a common set of outcomes would further guide clinical practice.
{"title":"Patients Receiving Integrative Medicine Effectiveness Registry (PRIMIER) of the BraveNet practice-based research network: Results of the chronic pain cohort","authors":"Jeffery A. Dusek , Qi Gao , Ryung S. Kim , Donald I. Abrams , Benjamin Kligler , Natalie L. Dyer , Kathryn Hansen , Eric J. Roseen , M. Diane McKee , the PRIMIER Writing Group*","doi":"10.1016/j.imr.2025.101141","DOIUrl":"10.1016/j.imr.2025.101141","url":null,"abstract":"<div><h3>Background</h3><div>An increasing number of clinics are providing integrative medicine for chronic pain, creating a need for real-world, practice-based research. Our purpose was to conduct a multi-site prospective, practice-based, observational evaluation of patient reported outcomes in chronic pain patients.</div></div><div><h3>Methods</h3><div>This study took place at seventeen BraveNet Practice Based Research Network integrative medicine clinics. Chronic pain patients receiving personalized, integrative medicine interventions at BraveNet clinics were eligible. Participants completed the Patient Reported Outcomes Measurement Information System-29, Perceived Stress Scale-4, and the Patient Activation Measure at the index/baseline visit and at 2, 4, 6, and 12 months. Diagnostic and billing codes were extracted data from patients’ health records. Linear mixed-model and multi-variate analyses evaluated changes from index visit through 12 months.</div></div><div><h3>Results</h3><div>A total of 4883 patients enrolled, 3658 qualified and 967 of them endorsed chronic pain, completed at least two outcomes at 2 time points, had evaluable electronic health record data, and had at least one integrative medicine visit during the study period. Participants had a mean age of 51.6 years (SD 13.88) and were mostly white (81.8 %), female (78.3 %), educated (≥ college degree: 70.1 %). Significant improvements were observed on all 7 Patient Reported Outcomes Measurement Information System subscales, Perceived Stress Scale, and Patient Activation Measure scores at 12 months.</div></div><div><h3>Conclusions</h3><div>Chronic pain patients receiving care at integrative medicine clinics reported significant improvement over time in multiple domains of pain and quality of life. Future research with more sites and a common set of outcomes would further guide clinical practice.</div></div><div><h3>Trial Registration</h3><div>Clinical Trials.gov NCT01754038</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101141"},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-20DOI: 10.1016/j.imr.2025.101138
Carolyn C Ee , Ieman Al-Kanini , Mike Armour , Milan K Piya , Rita McMorrow , Vibhuti S Rao , Dhevaksha Naidoo , Maria-Inti Metzendorf , Cynthia M Kroeger , Angelo Sabag
Background
Type 2 diabetes mellitus (T2DM) can lead to macro- and microvascular complications. Mindfulness-based interventions (MBIs) may improve metabolic and psychological health in individuals with T2DM. We aimed to assess the efficacy of MBIs for management of T2DM.
Methods
We searched five databases and two trial registries using a comprehensive search strategy developed by a multidisciplinary team including an information scientist. We included randomised controlled trials (RCTs) investigating MBIs for important clinical outcomes including psychological outcomes, quality of life, glycaemic control and cardiovascular risk factors in adults with T2DM. Where possible, random effects meta-analyses were conducted. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach was used to assess certainty of the evidence.
Results
We included 31 RCTs (2337 participants: 1107 intervention, 1230 control). We found very low certainty evidence that MBIs may reduce stress (standardized mean difference (SMD) –1.01, confidence interval (CI) –1.91 to –0.20, 8 trials, n = 528), depression (SMD –1.26, CI –2.08 to –0.43; 7 trials, n = 570) and anxiety (SMD –0.67, CI –1.27 to –0.08; 4 studies, n = 255) at end of treatment compared to waitlist control/usual care. MBIs may have a small effect on HbA1c and systolic/diastolic blood pressure at end of treatment compared to waitlist control/usual care (HbA1c mean difference (MD) –0.44, 95 % CI –0.71 to –0.17, 9 trials, n = 734; low certainty evidence). There was very low certainty evidence that MBIs + lifestyle may have no effect on HbA1c or body weight compared to lifestyle alone.
Conclusion
MBIs may have clinical benefits (particularly psychological) for adults with T2DM, but lack of certainty in the evidence precludes clinical recommendations.
Protocol registration
Cochrane Database of Systematic Reviews, DOI: 10.1002/14651858.CD014881.
背景2型糖尿病（T2DM）可导致大血管和微血管并发症。正念干预（MBIs）可以改善T2DM患者的代谢和心理健康。我们的目的是评估mbi治疗T2DM的疗效。方法：我们使用包括一位信息科学家在内的多学科团队开发的综合检索策略，检索了5个数据库和2个试验注册库。我们纳入了随机对照试验（RCTs），研究mbi对成年T2DM患者的重要临床结果，包括心理结果、生活质量、血糖控制和心血管危险因素的影响。在可能的情况下，进行随机效应荟萃分析。采用推荐、评估、发展和评价分级（GRADE）方法评估证据的确定性。结果纳入31项随机对照试验（2337名受试者：干预1107名，对照组1230名）。我们发现非常低确定性的证据表明mbi可以减轻压力(标准化平均差（SMD) -1.01，可信区间(CI) -1.91至-0.20,8项试验，n = 528），抑郁(SMD -1.26, CI -2.08至-0.43；7项试验，n = 570)和焦虑(SMD -0.67, CI -1.27至-0.08；4项研究，n = 255)在治疗结束时与等候名单对照/常规护理相比。与等候名单对照/常规治疗相比，mbi对治疗结束时HbA1c和收缩压/舒张压的影响较小(HbA1c平均差值(MD) -0.44, 95 % CI -0.71至-0.17,9项试验，n = 734；低确定性证据)。有非常低的确定性证据表明，与单独的生活方式相比，mbi +生活方式可能对HbA1c或体重没有影响。结论：mbis对成人2型糖尿病患者可能有临床益处（尤其是心理上的），但缺乏确定性的证据妨碍了临床推荐。cochrane系统评价数据库，DOI: 10.002 /14651858. cd014881。
{"title":"Mindfulness-based interventions for adults with type 2 diabetes mellitus: A systematic review and meta-analysis","authors":"Carolyn C Ee , Ieman Al-Kanini , Mike Armour , Milan K Piya , Rita McMorrow , Vibhuti S Rao , Dhevaksha Naidoo , Maria-Inti Metzendorf , Cynthia M Kroeger , Angelo Sabag","doi":"10.1016/j.imr.2025.101138","DOIUrl":"10.1016/j.imr.2025.101138","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes mellitus (T2DM) can lead to macro- and microvascular complications. Mindfulness-based interventions (MBIs) may improve metabolic and psychological health in individuals with T2DM. We aimed to assess the efficacy of MBIs for management of T2DM.</div></div><div><h3>Methods</h3><div>We searched five databases and two trial registries using a comprehensive search strategy developed by a multidisciplinary team including an information scientist. We included randomised controlled trials (RCTs) investigating MBIs for important clinical outcomes including psychological outcomes, quality of life, glycaemic control and cardiovascular risk factors in adults with T2DM. Where possible, random effects meta-analyses were conducted. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach was used to assess certainty of the evidence.</div></div><div><h3>Results</h3><div>We included 31 RCTs (2337 participants: 1107 intervention, 1230 control). We found very low certainty evidence that MBIs may reduce stress (standardized mean difference (SMD) –1.01, confidence interval (CI) –1.91 to –0.20, 8 trials, <em>n</em> = 528), depression (SMD –1.26, CI –2.08 to –0.43; 7 trials, <em>n</em> = 570) and anxiety (SMD –0.67, CI –1.27 to –0.08; 4 studies, <em>n</em> = 255) at end of treatment compared to waitlist control/usual care. MBIs may have a small effect on HbA1c and systolic/diastolic blood pressure at end of treatment compared to waitlist control/usual care (HbA1c mean difference (MD) –0.44, 95 % CI –0.71 to –0.17, 9 trials, <em>n</em> = 734; low certainty evidence). There was very low certainty evidence that MBIs + lifestyle may have no effect on HbA1c or body weight compared to lifestyle alone.</div></div><div><h3>Conclusion</h3><div>MBIs may have clinical benefits (particularly psychological) for adults with T2DM, but lack of certainty in the evidence precludes clinical recommendations.</div></div><div><h3>Protocol registration</h3><div>Cochrane Database of Systematic Reviews, DOI: 10.1002/14651858.CD014881.</div></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"14 2","pages":"Article 101138"},"PeriodicalIF":2.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143892235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号